Immunopathogenesis of thyroid eye disease: emerging paradigms

Area of Science:

• Endocrinology
• Immunology
• Ophthalmology

Background:

• Graves disease is a systemic autoimmune disorder affecting the thyroid, orbit, and skin.
• While thyroid dysfunction is treatable, effective therapies for orbital Graves disease (thyroid eye disease) remain limited.
• Thyroid eye disease involves inflammation, orbital fat expansion, and extracellular matrix deposition.

Purpose of the Study:

• To explore potential autoantigens involved in thyroid eye disease pathogenesis.
• To investigate the role of insulin-like growth factor-1 receptor (IGF-1R) in the extra-thyroidal manifestations of Graves disease.
• To identify novel therapeutic strategies targeting the molecular mechanisms of thyroid eye disease.

Main Methods:

• Analysis of autoantibodies against the thyrotropin receptor and IGF-1R in Graves disease patients.
• Assessment of IGF-1R expression in orbital fibroblasts and immune cells (T and B cells).
• Evaluation of cytokine actions and molecular interactions within the orbital environment.

Main Results:

• Activating antibodies against the thyrotropin receptor are common in Graves disease, driving hyperthyroidism.
• IGF-1R is overexpressed in orbital fibroblasts from thyroid eye disease patients.
• IGF-1R-expressing T and B cells are more prevalent in Graves disease patients.

Conclusions:

• Stimulating antibodies against IGF-1R may contribute to the orbital manifestations of Graves disease.
• Understanding the molecular interplay in the orbit provides new therapeutic avenues.
• Novel strategies may specifically interrupt the pathogenesis of thyroid eye disease.